文献速递前列腺癌

瑞格列克与亮丙瑞林在晚期前列腺癌男性中的睾酮恢复:3期HERO研究结果

Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
PubMed 文献 · Eur Urol Oncol · 2023-12-23

HERO研究预设亚组分析纳入934例随机(2:1)接受瑞格列克120 mg口服每日一次或亮丙瑞林每12周注射共48周的男性,其中184例完成48周治疗者评估停药后90天睾酮恢复。瑞格列克组睾酮恢复至>280 ng/dl的90天累积发生率54% vs 亮丙瑞林组3.2%(名义p=0.002),中位恢复时间86.0天 vs 112.0天。

要点

  • 瑞格列克组90天睾酮恢复至>280 ng/dl累积发生率54%,亮丙瑞林组3.2%(名义p=0.002)。
  • 瑞格列克组中位睾酮恢复时间86.0天,短于亮丙瑞林组112.0天。
  • 瑞格列克组39%达到基线睾酮≥80%,亮丙瑞林组2.1%。

核心结论

  • 在HERO研究预设亚组中,停用口服瑞格列克后睾酮恢复至正常水平比亮丙瑞林更快、更完全。
  • 作者认为瑞格列克更快的睾酮恢复对接受雄激素剥夺治疗的男性可能有重要临床意义,并可能影响治疗决策。

研究设计与样本

  • HERO研究预设亚组分析,男性N=934按2:1随机接受瑞格列克120 mg口服每日一次或亮丙瑞林每12周注射共48周。
  • 睾酮恢复在完成48周治疗的184例男性中评估,停药后90天恢复期内评估睾酮恢复时间(>280 ng/dl;≥基线睾酮80%)、血清前列腺特异性抗原和垂体激素水平及不良事件。

主要发现

  • 停药后90天睾酮恢复至>280 ng/dl的累积发生率瑞格列克组(n=137)54% vs 亮丙瑞林组(n=47)3.2%(名义p=0.002)。
  • 中位睾酮恢复时间瑞格列克组86.0天 vs 亮丙瑞林组112.0天。
  • 达到基线睾酮≥80%的比例瑞格列克组39% vs 亮丙瑞林组2.1%。
  • 年龄≤65岁及基线睾酮高于中位数的男性睾酮恢复发生率更高。
  • 不良事件在两组间总体相似。

关键数值与推荐

  • 睾酮恢复定义为>280 ng/dl且≥基线睾酮80%。
  • 90天睾酮恢复至>280 ng/dl累积发生率瑞格列克组54% vs 亮丙瑞林组3.2%(名义p=0.002)。
  • 中位睾酮恢复时间瑞格列克组86.0天 vs 亮丙瑞林组112.0天。
  • 达到基线睾酮≥80%的比例瑞格列克组39% vs 亮丙瑞林组2.1%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 睾酮恢复随访期短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the HERO study, relugolix demonstrated sustained testosterone suppression superior to that of leuprolide acetate (97% vs 89%; difference 7.9% [95% confidence interval, 4.1-12%; p < 0.001]). OBJECTIVE: To analyze testosterone recovery in a prespecified subset of men from the HERO study not indicated to continue androgen deprivation therapy. DESIGN, SETTING, AND PARTICIPANTS: Men (N = 934) were randomized (2:1) to receive relugolix 120 mg orally daily or leuprolide acetate injections every 12 wk for 48 wk. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Testosterone recovery was assessed in 184 men who completed 48 wk of treatment. During the 90-d recovery period, assessments included time to testosterone recovery (>280 ng/dl; ≥80% of baseline testosterone), serum levels of prostate-specific antigen and pituitary hormones, and adverse events. RESULTS AND LIMITATIONS: The cumulative incidence rate of testosterone recovery to >280 ng/dl at 90 d following drug discontinuation was significantly higher in the relugolix cohort (n = 137) than in the leuprolide acetate cohort (n = 47; 54% vs 3.2%; nominal p = 0.002). The median time to testosterone recovery was faster following relugolix treatment than with leuprolide acetate treatment (86.0 d vs 112.0 d). Compared with leuprolide acetate, more men treated with relugolix achieved ≥80% of baseline testosterone levels (39% vs 2.1%). Men ≤65 yr and those with baseline testosterone greater than the median had a higher incident rate of testosterone recovery. Adverse events were generally similar between treatment groups. One limitation is the short testosterone recovery follow-up period. CONCLUSIONS: Oral relugolix had faster and more complete recovery of testosterone to normal levels after treatment discontinuation than leuprolide acetate in a subset of men from the HERO study. The clinical implications of a faster testosterone recovery with relugolix may be significant for men being treated with androgen deprivation therapy and influence treatment decisions. PATIENT SUMMARY: The male hormone testosterone is reduced during androgen deprivation therapy for prostate cancer. Reduced testosterone levels cause side effects, impacting patient quality of life. When treatment is stopped, the side effects lessen over time as the levels of testosterone come back to pretreatment range (testosterone recovery). In this study, we found that the time to testosterone recovery was faster with relugolix than with leuprolide acetate.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Tutrone R, Saad F, George DJ, et al. Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. Eur Urol Oncol. 2023. PMID: 38143206. doi:10.1016/j.euo.2023.11.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。